시장보고서

상품코드

1506123

재발성 악성 신경교종 : 시장 인사이트, 역학 및 시장 예측(-2034년)

Recurrent Malignant Glioma - Market Insight, Epidemiology, and Market Forecast - 2034

발행일: On demand Report | 리서치사:

DelveInsight | 페이지 정보: 영문 200 Pages | 배송안내 : 2-10일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

샘플 요청 목록에 추가

이 보고서는 미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본 등 7개 주요 재발성 악성 신경교종 시장을 조사 분석하여 각 지역 시장 규모, 현재 치료법, 미충족 수요, 새로운 치료법 등에 대한 정보를 제공합니다.

조사 개요

재발성 악성 신경교종 시장은 향후 몇 년동안 이 질환에 대한 인식이 높아지고 전 세계 의료비 증가로 인해 변화할 것입니다.
기업과 연구기관들은 재발성 악성 신경교종 연구개발에 영향을 미칠 수 있는 과제를 평가하고 기회를 모색하기 위해 노력하고 있습니다. 개발 중인 치료법은 병태생리를 치료/개선하기 위한 새로운 접근법에 초점을 맞추었습니다.
주요 기업들이 재발성 악성 신경교종 치료제 개발에 참여하고 있습니다. 새로운 치료법의 출시는 재발성 악성 신경교종 시장에 큰 영향을 미칠 것입니다.
질병의 병태에 대한 더 깊은 이해는 재발성 악성 신경교종에 대한 새로운 치료법 개발에도 기여할 것입니다.
각기 다른 개발 단계(Phase III 및 Phase II)의 파이프라인 자산에 대한 상세한 분석, 새로운 동향, 각 파이프라인 제품의 비교 분석(상세한 임상 프로파일, 주요 교차 경쟁사, 제품 출시일 및 개발 활동 등)과 같은 정보는 R&D 활동의 전체 시나리오를 치료 포트폴리오에 대한 의사결정 과정에서 고객을 지원할 수 있도록 지원합니다.

역학 주요 조사 결과
전제조건과 근거 : 주요 7개 시장
역학 시나리오 : 주요 7개 시장
- 주요 7개 시장의 재발성 악성 신경교종 역학 시나리오(2020-2034년)
미국의 역학
- 미국의 재발성 악성 신경교종 역학 시나리오(2020-2034년)
유럽 5개국의 역학 : 국가별
- 독일
- 프랑스
- 이탈리아
- 스페인
- 영국
- 일본

제8장 치료 알고리즘, 현재 치료, 의료 행위

재발성 악성 신경교종 치료와 관리
재발성 악성 신경교종 치료 알고리즘

제9장 미충족 요구

제10장 재발성 악성 신경교종 치료의 주요 평가항목

제11장 출시 제품

제12장 새로운 치료법

제13장 재발성 악성 신경교종 : 주요 7개 시장 분석

주요 조사 결과
주요 7개 시장 재발성 악성 신경교종 시장 규모
주요 7개 시장 재발성 악성 신경교종 시장 규모 : 치료법별

제14장 속성 분석

제15장 주요 7개 시장 : 시장 전망

미국 : 시장 규모
- 미국의 재발성 악성 신경교종 전체 시장 규모
- 미국의 재발성 악성 신경교종 시장 규모 : 치료법별
유럽 5개국 : 시장 규모와 전망
독일 : 시장 규모
- 독일의 재발성 악성 신경교종 전체 시장 규모
- 독일의 재발성 악성 신경교종 시장 규모 : 치료법별
프랑스 시장 규모
이탈리아 시장 규모
스페인 시장 규모
영국 : 시장 규모
- 영국의 재발성 악성 신경교종 전체 시장 규모
- 영국의 재발성 악성 신경교종 시장 규모 : 치료법별
일본 시장 전망
- 일본 시장 규모

제16장 재발성 악성 신경교종 접근 및 상환 개요

제17장 KOL(Key Opinion Leader)의 견해

제18장 시장 성장 촉진요인

제19장 시장 성장 억제요인

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight에 대해

LSH 24.07.22

DelveInsight's "Recurrent Malignant Glioma - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Recurrent Malignant Glioma, historical and forecasted epidemiology as well as the Recurrent Malignant Glioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Recurrent Malignant Glioma market report provides current treatment practices, emerging drugs, Recurrent Malignant Glioma market share of the individual therapies, current and forecasted Recurrent Malignant Glioma market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Recurrent Malignant Glioma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2020-2034

Recurrent Malignant Glioma Disease Understanding and Treatment Algorithm

The DelveInsight Recurrent Malignant Glioma market report gives a thorough understanding of the Recurrent Malignant Glioma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Recurrent Malignant Glioma.

Treatment

It covers the details of conventional and current medical therapies available in the Recurrent Malignant Glioma market for the treatment of the condition. It also provides Recurrent Malignant Glioma treatment algorithms and guidelines in the United States, Europe, and Japan.

Recurrent Malignant Glioma Epidemiology

The Recurrent Malignant Glioma epidemiology division provide insights about historical and current Recurrent Malignant Glioma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Recurrent Malignant Glioma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Recurrent Malignant Glioma Epidemiology

The epidemiology segment also provides the Recurrent Malignant Glioma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Recurrent Malignant Glioma Drug Chapters

Drug chapter segment of the Recurrent Malignant Glioma report encloses the detailed analysis of Recurrent Malignant Glioma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Recurrent Malignant Glioma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Recurrent Malignant Glioma treatment.

Recurrent Malignant Glioma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Recurrent Malignant Glioma treatment.

Recurrent Malignant Glioma Market Outlook

The Recurrent Malignant Glioma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Recurrent Malignant Glioma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Recurrent Malignant Glioma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Recurrent Malignant Glioma market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Recurrent Malignant Glioma market in 7MM.

The United States Market Outlook

This section provides the total Recurrent Malignant Glioma market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Recurrent Malignant Glioma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Recurrent Malignant Glioma market size and market size by therapies in Japan is also mentioned.

Recurrent Malignant Glioma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Recurrent Malignant Glioma market or expected to get launched in the market during the study period 2020-2034. The analysis covers Recurrent Malignant Glioma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Recurrent Malignant Glioma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Recurrent Malignant Glioma key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Recurrent Malignant Glioma emerging therapies.

Reimbursement Scenario in Recurrent Malignant Glioma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Recurrent Malignant Glioma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Recurrent Malignant Glioma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Recurrent Malignant Glioma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of Recurrent Malignant Glioma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Recurrent Malignant Glioma epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Recurrent Malignant Glioma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Recurrent Malignant Glioma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Recurrent Malignant Glioma market

Report Highlights:

In the coming years, Recurrent Malignant Glioma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Recurrent Malignant Glioma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Recurrent Malignant Glioma. Launch of emerging therapies will significantly impact the Recurrent Malignant Glioma market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Recurrent Malignant Glioma
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Recurrent Malignant Glioma Report Insights

Patient Population
Therapeutic Approaches
Recurrent Malignant Glioma Pipeline Analysis
Recurrent Malignant Glioma Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Recurrent Malignant Glioma Report Key Strengths

11 Years Forecast
7MM Coverage
Recurrent Malignant Glioma Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Recurrent Malignant Glioma Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions:

Market Insights:

What was the Recurrent Malignant Glioma market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Recurrent Malignant Glioma total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Recurrent Malignant Glioma market size during the forecast period (2024-2034)?
At what CAGR, the Recurrent Malignant Glioma market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Recurrent Malignant Glioma market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Recurrent Malignant Glioma market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Recurrent Malignant Glioma?
What is the historical Recurrent Malignant Glioma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Recurrent Malignant Glioma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Recurrent Malignant Glioma?
Out of all 7MM countries, which country would have the highest prevalent population of Recurrent Malignant Glioma during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Recurrent Malignant Glioma treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Recurrent Malignant Glioma in the USA, Europe, and Japan?
What are the Recurrent Malignant Glioma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Recurrent Malignant Glioma?
How many therapies are developed by each company for Recurrent Malignant Glioma treatment?
How many are emerging therapies in mid-stage, and late stage of development for Recurrent Malignant Glioma treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Recurrent Malignant Glioma therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Recurrent Malignant Glioma and their status?
What are the key designations that have been granted for the emerging therapies for Recurrent Malignant Glioma?
What are the global historical and forecasted market of Recurrent Malignant Glioma?

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving the Recurrent Malignant Glioma market
To understand the future market competition in the Recurrent Malignant Glioma market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Recurrent Malignant Glioma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Recurrent Malignant Glioma market
To understand the future market competition in the Recurrent Malignant Glioma market

1. Key Insights

2. Executive Summary of Recurrent Malignant Glioma

3. Competitive Intelligence Analysis for Recurrent Malignant Glioma

4. Recurrent Malignant Glioma: Market Overview at a Glance

4.1. Recurrent Malignant Glioma Total Market Share (%) Distribution in 2020
4.2. Recurrent Malignant Glioma Total Market Share (%) Distribution in 2034

5. Recurrent Malignant Glioma: Disease Background and Overview

5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. Recurrent Malignant Glioma Epidemiology and Patient Population

7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
- 7.3.1. Recurrent Malignant Glioma Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
- 7.4.1. Recurrent Malignant Glioma Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
- 7.5.1. Germany Epidemiology
  - 7.5.1.1. Recurrent Malignant Glioma Epidemiology Scenario in Germany (2020-2034)
- 7.5.2. France Epidemiology
  - 7.5.2.1. Recurrent Malignant Glioma Epidemiology Scenario in France (2020-2034)
- 7.5.3. Italy Epidemiology
  - 7.5.3.1. Recurrent Malignant Glioma Epidemiology Scenario in Italy (2020-2034)
- 7.5.4. Spain Epidemiology
  - 7.5.4.1. Recurrent Malignant Glioma Epidemiology Scenario in Spain (2020-2034)
- 7.5.5. United Kingdom Epidemiology
  - 7.5.5.1. Recurrent Malignant Glioma Epidemiology Scenario in the United Kingdom (2020-2034)
- 7.5.6. Japan Epidemiology
  - 7.5.6.1. Recurrent Malignant Glioma Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Recurrent Malignant Glioma Treatment and Management
8.2. Recurrent Malignant Glioma Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Recurrent Malignant Glioma Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Pivotal Clinical Trials
- 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross
12.2. Drug Name: Company Name
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
- 12.2.5. Product Profile